Eli Lilly & Company

Type: Company
Name: Eli Lilly & Company (Eli Lilly and Company)
First reported 1 hour ago - Updated 1 hour ago - 1 reports

UCSD raises $1.1 billion for research

UC San Diego raised almost $1.1 billion for research over the past year, maintaining the school’s standing as one of the nation’s 10 largest centers for science, engineering and medicine.The money is being used to do everything from search for ways to ... [Published U-T San Diego - 1 hour ago]
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Expect Gilead Sciences To Outperform

By David Sims :Target PriceRelated Biotechnology, Pharmaceutical and Healthcare NewsThe author sets a target price for Gilead Sciences (NASDAQ: GILD ) common stock at $125.Target Price ExplanationBased on comparable valuations for the industry, the stock ... [Published BioPortfolio - 1 hour ago]
First reported 2 hours ago - Updated 2 hours ago - 1 reports

Roche trial helps Lilly on Alzheimer’s

Now Indianapolis-based Lilly has company. This month, Switzerland-based Roche presented results of its Alzheimer’s drug, and the result was remarkably alike.The two Phase 3 trials of the drug failed to show meaningful effect in the patients studied. Yet, ... [Published Indianapolis Business Journal - 2 hours ago]
First reported 2 hours ago - Updated 2 hours ago - 1 reports

Watch for Shares of Eli Lilly (LLY) to Approach Support at $63.18

Shares of Eli Lilly (NYSE:LLY) opened today below their pivot of $63.79 and have already reached the first level of support at $63.48. Analysts will be watching for a cross of the next downside pivot targets of $63.18 and $62.57. ... [Published Individual.com - 2 hours ago]
First reported 5 hours ago - Updated 5 hours ago - 1 reports

Top 10 animal health companies of 2013

It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound annual rate, faster than the market for human medic ... [Published Fierce CRO - 5 hours ago]
First reported 6 hours ago - Updated 6 hours ago - 1 reports

The Pfizer dilemma: Spurned by AstraZeneca, revenue falling and facing an R&D crisis

Pfizer is in a nasty fix. Tomorrow the pharma giant ($PFE) will release a rundown of its Q2 numbers--which won't be pretty--and CEO Ian Read and his top team will have plenty of explaining to do about how they plan to get out of the tight spot they find ... [Published FierceBiotech - 6 hours ago]
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Alzheimer’s therapies could result in $12B market by 2023

The industry for Alzheimer’s drug treatments is expected to grow from modest beginnings to big business in the next decade, according to a June report by Decision Resources Group.The analysis estimates that the market for Alzheimer’s therapies will more ... [Published MolecularImaging.net - 7 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

Anthera Pharmaceuticals Announces Acquisition of Sollpura liprotamase for Exocrine Pancreatic Insufficiency From Eli Lilly and Company

By a News Reporter-Staff News Editor at Clinical Trials Week Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) announced that it has acquired Sollpura (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy ("PERT") from Eli Lilly and ... [Published Pharmacy Choice - 9 hours ago]
First reported 22 hours ago - Updated 22 hours ago - 1 reports

Eli Lilly copy of $8 billion Sanofi insulin wins EU green light

European regulators have for the first time recommended approval of Eli Lilly’s Abasaria, a bio-similar version of Sanofi’s Lantus, which generates approximately $8 billion in yearly sales, as reported in Yahoo!7 News. The European Medicines Agency (EMA), ... [Published FirstWord Pharma - 22 hours ago]
First reported 23 hours ago - Updated 23 hours ago - 1 reports

How Your Diet Affects Your Mental Health

Over the last half century, the global food industry has profoundly changed the way we eat. While we understand how these dietary changes have impacted physical health, their effect on mental well-being is only now being realised.Eating picture from ... [Published Lifehacker Australia - 23 hours ago]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

Eli Lilly and Receives Neutral Rating from Zacks (LLY)

Eli Lilly and (NYSE:LLY)Zacks’ analyst wrote, "Lilly’s second quarter 2014 EPS of $0.68 were a couple of cents above the Zacks Consensus Estimate but 41% below the year-ago EPS. Revenues slipped 17% to $4.935 billion, missing the Zacks Consensus Estimate ... [Published American Banking News - Jul 26 2014]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

Pharmaceuticals companies shares down at the close of trading

NEW YORK –   Shares of some top pharmaceuticals companies were down at the close of trading:Baxter International Inc. fell $.35 or .5 percent, to $76.65.Bristol-Myers Squibb Co. fell $.07 or .1 percent, to $49.39.Hospira fell $.10 or .2 percent, to $ ... [Published FOXBusiness.com - Jul 26 2014]

Quotes

"Cathy has been a force for action wherever she's been throughout her career, and I know we are going to go great places with her. I look forward to working with Cathy."
However, after about 50 years of study in rats, "the human clinical data are just at the point where I think we need to get serious about trying to"
Mark Schoenebaum, the big pharma specialist at ISI, noted over the weekend that Pfizer needs to "explain (again) why you went after AZN and why PFE is OK without it." Not only that, he adds, Pfizer needs to "show us the goods" in the pipeline and see if it can generate some excitement, as well as explain why it shouldn't...
...But he acknowledged that the Novartis deal not only makes GSK stronger as a whole, but strengthens its various units as entities unto themselves. "Through our transaction with Novartis we are making all of our businesses stronger together and stronger as individual components" Witty said, adding that the deal adds value to Glaxo overall

More Content

All (1794) | News (1304) | Reports (0) | Blogs (435) | Audio/Video (1) | Fact Sheets (18) | Press Releases (30)
sort by: Date | Relevance
UCSD raises $1.1 billion for research [Published U-T San Diego - 1 hour ago]
Expect Gilead Sciences To Outperform [Published BioPortfolio - 1 hour ago]
Paul Smith's chooses new leader [Published Press-Republican Online - 2 hours ago]
Brown Fat May Protect Against Diabetes and Obes... [Published Diabetes Care - 2 hours ago]
Roche trial helps Lilly on Alzheimer’s [Published Indianapolis Business Journal - 2 hours ago]
Drugs to increase 'good' cholesterol may not cu... [Published Yahoo! Canada - 2 hours ago]
Expect Gilead Sciences To Outperform [Published Seeking Alpha - 2 hours ago]
Viral Agent [Published TheWalrus.ca - 2 hours ago]
Watch for Shares of Eli Lilly (LLY) to Approach... [Published Individual.com - 2 hours ago]
Top 10 animal health companies of 2013 [Published Fierce CRO - 5 hours ago]
VYM, MCD, OXY, LLY: Large Inflows Detected at ETF [Published Self Directed Investor - 5 hours ago]
The Pfizer dilemma: Spurned by AstraZeneca, rev... [Published FierceBiotech - 6 hours ago]
GlaxoSmithKline CEO: Open to spinning off consu... [Published FiercePharma - 6 hours ago]
Alzheimer’s therapies could result in $12B mark... [Published MolecularImaging.net - 7 hours ago]
Global insulin market set to reach $32.24 billi... [Published Pharma Letter - 8 hours ago]
TransCelerate taps Cognizant to get its Big Pha... [Published Fierce CRO - 8 hours ago]
Eli Lilly (LLY) Showing Bullish Technicals With... [Published MarketIntelligenceCenter.com - 9 hours ago]
Anthera Pharmaceuticals Announces Acquisition o... [Published Pharmacy Choice - 9 hours ago]
Protein Drugs Market: Pharmaceutical Industry 2019 [Published MyNewsDesk - 10 hours ago]
Systemic Lupus Erythematosus Market Forecast an... [Published MyNewsDesk - 11 hours ago]
MKU confers honorary degree on scientist Njoroge [Published The Star (Kenya) - 12 hours ago]
G1, Out to Shield Body From Chemo, Heads to Fir... [Published Xconomy - 17 hours ago]
Eli Lilly copy of $8 billion Sanofi insulin win... [Published FirstWord Pharma - 22 hours ago]
How Your Diet Affects Your Mental Health [Published Lifehacker Australia - 23 hours ago]
TransCelerate selects Cognizant to develop subs... [Published Center Watch - Jul 27 2014]
Top 3 Ways to Profit From the Tax Inversion M&A... [Published Investors Alley - Jul 27 2014]
Viagra price drop to boost sales [Published Melbourne Age - Jul 26 2014]
MRC Links With 7 Big Pharma Firms For Drug Rese... [Published Pharmaceutical Online - Jul 26 2014]
Eli Lilly and Receives Neutral Rating from Zack... [Published American Banking News - Jul 26 2014]
Pharmaceuticals companies shares down at the cl... [Published FOXBusiness.com - Jul 26 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Eli Lilly (LLY) Showing Bullish Technicals With... [Published MarketIntelligenceCenter.com - 9 hours ago]
For a hedged play on Eli Lilly and Co (LLY) MarketIntelligenceCenter.com’s algorithms selected the Sep. '14 $65.00 covered call for a net debit in the $62.95 area. That is also the break-even stock price for the covered call. This trade will return 3.26%, ...
Potential Eli Lilly (LLY) Trade Targets 2.73% R... [Published MarketIntelligenceCenter.com - Jul 25 2014]
For a hedged play on Eli Lilly and Co (LLY) MarketIntelligenceCenter.com’s patented trade-picking algorithms selected a Sep. '14 $65.00 covered call for a net debit in the $63.27 area. That is also the break-even stock price for the covered call. This ...
GLOBAL MARKETS-Stocks gain, U.S. bonds fall on ... [Published AdBanks.net - Jul 24 2014]
* U.S. stocks edge up along with MSCI world index * Facebook shares hit record high * Russian debt insurance costs rise on EU sanctions * US homebuilders down after housing data (Adds homebuilder shares and other details, updates trading) ...
Lilly CEO sees margins hitting pre-patent cliff... [Published FOX Business - Video - Jul 24 2014]
Eli Lilly CEO John Lechleiter discusses 2Q earnings and the impact of recent patent expirations. ...
Frontrunning: July 24 [Published Zero Hedge - Jul 24 2014]
EU to weigh extensive sanctions on Russia ( FT ) U.S. lifts flight ban to Israel ( Reuters ) Russia says will cooperate with MH17 probe led by Netherlands ( Reuters ) Norway faces ‘concrete and credible’ terrorist threat ( FT ) Don’t Tell Anybody About ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
Economy Grows At A Healthy Clip [Published Wall Street Journal What's News - Jan 30 2014]
1

Press Releases

sort by: Date | Relevance
Biotechnology Sector Trends Higher with Breakth... [Published Financial Services - Jul 16 2014]
Anthera Pharmaceuticals Announces Acquisition o... [Published Financial Services - Jul 14 2014]
Clinical Trial Update, Recommendations for Appr... [Published Financial Services - Jul 02 2014]
Pharma Equities Technical Coverage -- Research ... [Published Financial Services - Jun 23 2014]
Type 2 diabetes: Boehringer Ingelheim and Eli L... [Published Financial Services - Jun 17 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.